PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: An open label, single-group, phase 2 trial

Investigational New Drugs

Volumn 32, Issue 3, 2014, Pages 555-560

  Necchi, A ^a   Giannatempo, P ^a   Mariani, L ^a   Fare E ^a   Raggi, D ^a   Pennati, M ^a   Zaffaroni, N ^a   Crippa, F ^a   Marchiano A ^a   Nicolai, N ^a   Maffezzini, M ^a   Togliardi, E ^a   Daidone, M G ^a   Gianni, A M ^a   Salvioni, R ^a   De Braud, F ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Advanced urothelial cancer; Angiogenesis; PF 03446962; Salvage therapy; Transitional cell carcinoma

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; CISPLATIN; DOXORUBICIN; INTERLEUKIN 8; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PF 03446962; PF 03446962; UNCLASSIFIED DRUG; VASCULOTROPIN; VINBLASTINE; VINFLUNINE; ACTIVIN RECEPTOR 2; ACVRL1 PROTEIN, HUMAN; ANGIOGENESIS INHIBITOR; PF-03446962;

ABDOMINAL PAIN; ADULT; AGE DISTRIBUTION; AGED; ANEMIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BELLMUNT SCORE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HUMAN; MALE; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUALITY OF LIFE; SALVAGE THERAPY; SCORING SYSTEM; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; UPREGULATION; VISCERAL METASTASIS; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; IMMUNOLOGY; MIDDLE AGED; UROLOGIC NEOPLASMS;

ACTIVIN RECEPTORS, TYPE II; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; MALE; MIDDLE AGED; UROLOGIC NEOPLASMS;

EID: 84904616246     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0074-9     Document Type: Article

References (30)

1. Sonpavde G, Sternberg CN, Rosenberg JE et al (2010) Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol 11:861-870
2. Balar AV, Apolo AB, Ostrovnaya I et al (2013) Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable ormetastatic urothelial cancer. J Clin Oncol 31:724-730
3. Bellmunt J, González-Larriba JL, Prior C et al (2011) Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast-enhancement as potential predictive factors of activity. Ann Oncol 22:2646-2653
4. Dreicer R, Li H, Stein M et al (2009) Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the eastern cooperative oncology group. Cancer 115:4090-4095
5. Gallagher DJ, Milowsky MI, Gerst SR et al (2010) Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol 28:1373-1379
6. Galsky MD, Hahn NM, Powles Tet al (2013) Gemcitabine, cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. Clin Genitourin Cancer 11:175-181
7. Hahn NM, Stadler WM, Zon RTet al (2011) Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier oncology group GU 04-75. J Clin Oncol 29:1525-1530
8. Milowsky MI, Iyer G, Regazzi AM et al (2013) Phase II study of everolimus in metastatic urothelial cancer. BJU Int 112:462-470
9. Necchi A, Mariani L, Zaffaroni N et al (2012) Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncol 13:810-816
10. Pili R, Qin R, Flynn PJ et al (2013) A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. Clin Genitourin Cancer 11:477-483
11. Seront E, Rottey S, Sautois B et al (2012) Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Ann Oncol 23:2663-2670
12. Grivas PD, Daignault S, Tagawa ST, et al (2013) Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer. doi:10.1002/cncr.28477
13. Bierie B, Moses HL (2006) TGFβ: the molecular Jeckyll and Hyde of cancer. Nat Rev Cancer 6:506-520
14. Champelovier P, El Atifi M, Mantel F et al (2005) In vitro tumoral progression of human bladder carcinoma: role for TGFbeta. Eur Urol 48:846-851 (Pubitemid 41495393)
15. Lamouille S, Mallet C, Feie JJ et al (2002) Activin receptor like kinase 1 is implicated in the maturation phase of angiogenesis. Blood 100:4495-4501 (Pubitemid 35429690)
16. Oh SP, Seki T, Goss KA et al (2000) Activin receptor like-kinase 1 modulates transforming growth factor-β1 signaling in the regulation of angiogenesis. PNAS 97:2626-2631 (Pubitemid 30159221)
17. Scharpfenecker M, van Dinther M, Liu Z et al (2007) BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J Cell Sci 120:964-972 (Pubitemid 46638511)
18. Hu-Lowe DD, Chen E, Zhang L et al (2011) Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies. Cancer Res 71:1362-1373
19. Goff L, Cohen RB, Berlin J, et al (2011) Phase I study of PF-03446962, a fully human mAb against ALK1, a TGFβ receptor involved in tumor angiogenesis. J Clin Oncol 29(suppl; abstr 3009)
20. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247
21. Young H, Baum R, Cremerius U et al (1999) Measurement of clinical and subclinical tumour response using (18 F)-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for the Research and Treatment of Cancer (EORTC) PET study group. Eur J Cancer 35:1773-1782 (Pubitemid 29512308)
22. Moro C, Brunelli C, Miccinesi G et al (2006) Edmonton symptom assessment scale: Italian validation in two palliative care settings. Support Care Cancer 14:30-37 (Pubitemid 43119594)
23. Bellmunt J, Choueiri TK, Fougeray R et al (2010) Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 28:1850-1855
24. Necchi A, Mariani L, Giannatempo P, et al (2013) Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer. Clin Genitourin Cancer. doi:10.1016/j.clgc.2013.11.022
25. Bendell JC, Gordon MS, Hurwits HI et al (2013) Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer. Clin Cancer Res 20:1-10
26. Bhatt RS, Wang X, Solban N, et al (2013) Inibition of tumor growth in a VEGFR TKI-resistant model of renal cell carcinoma using dalantercept combined with sunitinib. J Clin Oncol 31(suppl 6; abstr 370)
27. Atkins MB, Bhatt RS, Voss MH, et al (2013) Phase II randomized study of dalantercept in combination with axitinib compared to axitinib alone as second-line treatment in patients with metastatic renal cell carcinoma. J Clin Oncol 31(suppl; abstr TPS4595)
28. Jimeno A, Wirth LJ, Posner MR, et al (2013) Phase II study of dalantercept, a novel inhibitor of ALK1-mediated angiogenesis, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 31(suppl; abstr TPS6098)
29. Sonpavde G, Bellmunt J, Rosenberg JE, et al (2014) Impact of number of lines of prior chemotherapy in patients (pts)with advanced urothelial carcinoma (UC) receiving salvage therapy. J Clin Oncol 32 (suppl 4; abstr 353)
30. Sonpavde G, Bellmunt J, Rosenberg JE et al (2014) Impact of prior platinum agent and site of primary in patients with advanced urothelial carcinoma (UC) receiving salvage therapy. J Clin Oncol 32 (suppl 4; abstr 336)